Nathaniel Harding: Year in Review and 2024 Outlook

2023 Lookback for Cortado Ventures — Read the full story here At Cortado Ventures, we’re excited for 2024. In our company meeting this week, we strategized our position in the Midcontinent market and what it will take to source, select, and support the best and...

Why We Invested: Moat Biotechnology

At Cortado Ventures, we back entrepreneurs that are inventing the future, and we are thrilled about our investment in Moat Biotechnology. Moat’s technology is based on a next-generation adenovirus platform from the Mayo Clinic. Our General Partner Mike Moradi...